茚达特罗治疗极重度慢性阻塞性肺疾病患者的疗效及安全性观察

发布时间：2018-04-26 02:01

  本文选题：慢性阻塞性肺疾病 + 茚达特罗　； 参考：《实用医学杂志》2014年11期

【摘要】：目的:观察并分析茚达特罗在极重度通气功能障碍慢性阻塞性肺疾病(COPD)患者中的临床应用效果及安全性。方法:对处于稳定期,沙美特罗氟替卡松联合噻托溴铵吸入后仍然感觉呼吸困难的极重度通气功能障碍COPD患者,以茚达特罗替代沙美特罗氟替卡松,观察患者用药前和用药90 d后的肺功能指标、COPD评估测试(CAT)评分的变化。结果:患者用药90 d后用力肺活量(FVC)平均增加0.15 L,深吸气量(IC)平均增加0.51 L,均有较大的改善;FEV1与FEV1/FVC%变化不大;全部患者CAT评分比用药前平均下降8.7分,客观表现为呼吸困难的缓解和对生活质量影响程度降低,而且无合并症加重。结论:茚达特罗可以改善极重度通气功能障碍COPD患者的肺功能,改善患者呼吸困难状况,提高生活质量且有一定的安全性。
[Abstract]:Objective: to observe and analyze the clinical efficacy and safety of indendibuterol in patients with extremely severe ventilation dysfunction chronic obstructive pulmonary disease (COPDD). Methods: in patients with extremely severe ventilatory dysfunction (COPD) who were still feeling dyspnea after inhalation of salmeterol fluticasone combined with tiotropium, the patients with severe ventilatory dysfunction were treated with indoletriol instead of salmeterol fluticasone. Before and 90 days after treatment, the pulmonary function index and the score of COPD evaluation test (CAT) were observed. Results: after 90 days of treatment, forced vital capacity (FVC) and inspiratory volume (ICI) were increased by 0.15 L and 0.51 L, respectively. FEV1 and FEV1 / FVC% were significantly improved, and the CAT scores of all patients were decreased by 8.7 points compared with those before medication. The objective manifestation is the relief of dyspnea and the decrease of quality of life. Conclusion: indolebuterol can improve lung function of patients with extremely severe ventilation dysfunction (COPD), improve breathing condition, improve quality of life and have certain safety.
【作者单位】： 呼吸疾病国家重点实验室 国家呼吸疾病临床研究中心 广州医科大学附属第一医院 广州呼吸疾病研究所;
【分类号】：R563.9
，

本文编号：1803959